Eritoran: meta-analysis of COVID-19 studies

All studies   Mortality   Serious outcomes   RCTs   RCT mortality   Peer-reviewed   All outcomes  
Meta-analysis1 study · 96 patientsc19early.org

Eritoran for COVID-19

Serious outcome risk
Eritoran
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)−26%
Mortality (1)−26%
RCTs (1)−26%
Late (1)−26%
00.511.5+
← Eritoran
reduces riskIncreased
risk →
c19early.org
October 2026

Eritoran COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Saito (DB RCT)−26%1.26 · 0.43–3.74death4/462/50
Late treatment−26%1.26 · 0.24–6.564/462/5026% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.8
All studies−26%1.26 · 0.24–6.564/462/5026% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.800.511.52+
Rotate screen for more detailsIncrease width for more details
← Eritoran
reduces riskEritoran
increases risk →
c19early.org
October 2026

Eritoran COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Saito (DB RCT)−26%1.26 · 0.43–3.744/462/50
Late treatment−26%1.26 · 0.24–6.564/462/5026% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.8
All studies−26%1.26 · 0.24–6.564/462/5026% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.800.511.52+
Rotate screen for more detailsIncrease width for more details
← Eritoran
reduces riskEritoran
increases risk →
c19early.org
October 2026

Eritoran COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Saito (DB RCT)−26%1.26 · 0.43–3.74death4/462/50
Late treatment−26%1.26 · 0.24–6.564/462/5026% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.8
All studies−26%1.26 · 0.24–6.564/462/5026% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.800.511.52+
Rotate screen for more detailsIncrease width for more details
← Eritoran
reduces riskEritoran
increases risk →
c19early.org
October 2026

Eritoran COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Saito (DB RCT)−26%1.26 · 0.43–3.74death4/462/50
Late treatment−26%1.26 · 0.24–6.564/462/5026% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.8
All studies−26%1.26 · 0.24–6.564/462/5026% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.800.511.52+
Rotate screen for more detailsIncrease width for more details
← Eritoran
reduces riskEritoran
increases risk →
c19early.org
October 2026

Eritoran COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Saito (DB RCT)−26%1.26 · 0.43–3.744/462/50
Late treatment−26%1.26 · 0.24–6.564/462/5026% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.8
All studies−26%1.26 · 0.24–6.564/462/5026% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.800.511.52+
Rotate screen for more detailsIncrease width for more details
← Eritoran
reduces riskEritoran
increases risk →
c19early.org
October 2026

Eritoran COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Saito (DB RCT)−26%1.26 · 0.43–3.74death4/462/50
Late treatment−26%1.26 · 0.24–6.564/462/5026% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.8
All studies−26%1.26 · 0.24–6.564/462/5026% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.800.511.52+
Rotate screen for more detailsIncrease width for more details
← Eritoran
reduces riskEritoran
increases risk →